Table 3. Hypothetical vaccine coverage conferred by OMV vaccines against isolates in the PubMLST sample.

Trial	Vaccine	Antigens	No. Isolates in dataset (%)	Minimum utility of vaccine (years)*	Ref
Norway	MenBVac	P1.7,16:F3-3	66 (1.9)	35	[19]
New Zealand	MeNZB	P1.7-2,4	147 (4.3)	26	[20]
Cuba	VA-MENGOC-BC	P1.19,15:F5-1	270 (7.8)	36	[21]

^*Minimum utility was defined as the total period of time across which a given antigenic combination had been recorded in the PubMLST sample.